|March 20, 2013|
|07:16 EDT||BSX||Boston Scientific volatility at low end of historic range |
Boston Scientific overall option implied volatility of 30 is below its 26-week average of 33 according to Track Data, suggesting decreasing price movement.
News For BSX From The Last 14 Days
|October 20, 2014|
|08:16 EDT||BSX||Boston Scientific initiates PLATINUM Diversity trial|
Subscribe for More Information
|07:20 EDT||BSX||International Continence Society to hold annual meeting|
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.
|07:11 EDT||BSX||American Society for Reproductive Medicine to hold annual meeting|
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
|October 16, 2014|
|16:32 EDT||BSX||Boston Scientific announces pacemaker CE mark with options for MRI|
Boston Scientific has received CE Mark approval for the ACCOLADE pacemaker family. When implanted with the company's INGEVITY leads, ACCOLADE pacemakers are the first to enable patients to receive full-body MRI scans in both 1.5 Tesla and 3.0 Tesla systems. In addition, the Boston Scientific ImageReady technology offers the most flexible MRI options, allowing higher energy scan sequences, and featuring a programmable MRI timer designed to improve patient workflow. In addition to the CE mark approval and launch of the ACCOLADE pacemaker family, Boston Scientific received CE Mark approval for the VISIONIST and VALITUDE CRT-Ps with quadripolar pacing technology. When paired with the ACUITY X4 pacing leads, these systems offer many options to reach and pace the target location in the left ventricle, potentially improving the patient response to CRT therapy.
|15:10 EDT||BSX||American College of Gastroenterology to hold annual meeting|
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
|October 8, 2014|
|20:03 EDT||BSX||Boston Scientific confirms FDA panel votes for WATCHMAN device|
After reviewing updated data and analysis for the Boston Scientific Corporation WATCHMAN Left Atrial Appendage Closure Device, the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee voted in favor of the Device. By a vote of 6 to 5, with 1 abstention, the panel concluded that the benefits of the WATCHMAN Device outweigh the potential risks. The panel voted that there is reasonable assurance that the device is safe, with a 12 yes to 0 no vote. On the question of reasonable assurance of effectiveness, the panel vote was unfavorable with a 6 yes to 7 no vote. The panel provided substantial input and guidance related to the proposed Indications for use and target patient population. There was widespread agreement among the panel members that the device provides a much needed alternative to long-term anticoagulation for some patients. While not bound by this vote, the FDA takes Advisory Panel comments and recommendations into account when reviewing the WATCHMAN Device application. The company is committed to working with the FDA to address the panel's comments.
|18:42 EDT||BSX||Boston Scientific Watchman Device receives votes from FDA panel, Dow Jones says|
The FDA Panel voted 6 to 5 that benefits of Boston Scientific's Watchman device outweigh the risks, Dow Jones reports. The panel voted 12 to 0 that the Watchman device is safe, and the panel voted 7 to 6 that the Watchman device is not effective, Dow Jones added.
|07:24 EDT||BSX||FDA Circulatory Systems Devices Panel to hold a meeting|
The Committee discusses, makes recommendations and votes on information related to the Pre-Market Approval Application regarding Boston Scientificís WATCHMAN Left Atrial Appendage (LAA) Closure Technology in a meeting being held in Gaithersburg, Maryland on October 8 at 8 am. Webcast Link